Possible involvement of rho-kinase in aldosterone-induced vascular smooth muscle cell remodeling

Hypertension Research

Volumn 31, Issue 7, 2008, Pages 1407-1413

  Miyata, Kayoko ^a   Hitomi, Hirofumi ^a   Guo, Peng ^a   Zhang, Guo Xing ^a   Kimura, Shoji ^a   Kiyomoto, Hideyasu ^a   Hosomi, Naohisa ^a   Kagami, Shoji ^b   Kohno, Masakazu ^a   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Aldosterone; Eplerenone; Mineralocorticoid receptor; Rho kinase; Vascular smooth muscle cells

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALDOSTERONE; EPLERENONE; GUANOSINE TRIPHOSPHATE; MYOSIN; PROTEIN SUBUNIT; RHO KINASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; CYTOSKELETON; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ANALYSIS; MALE; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ACTINS; ALDOSTERONE; AMIDES; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTEIN PHOSPHATASE 1; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; RHO-ASSOCIATED KINASES;

EID: 55449120174     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1407     Document Type: Article

References (39)

1. Nishimura M, Uzu T, Fujii T, et al: Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261-266.
2. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
3. Pitt B, Remme W, Zannad F, et al, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
4. Takeda Y: Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004; 217: 75-79.
5. Yoshida K, Kim-Mitsuyama S, Wake R, et al: Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005; 28: 447-455.
6. Muiesan ML, Rizzoni D, Salvetti M, et al: Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 2002; 20: 1439-1444.
7. Park JB, Schiffrin EL: ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37: 1444-1449.
8. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106: 2848-2853.
9. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL: Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004; 43: 1252-1257.
10. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458.
11. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A: Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001; 104: 467-472.
12. Brown JH, Del Re DP, Sussman MA: The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006; 98: 730-742.
13. Loirand G, Guerin P, Pacaud P: Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334.
14. Moriki N, Ito M, Seko T, et al: RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 2004; 27: 263-270.
15. Hattori T, Shimokawa H, Higashi M, et al: Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 2004; 94: 46-52.
16. Higashi M, Shimokawa H, Hattori T, et al: Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93: 767-775.
17. Kanda T, Hayashi K, Wakino S, et al: Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension 2005; 45: 724-729.
18. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H: Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005; 28: 925-936.
19. Sun GP, Kohno M, Guo P, et al: Involvements of Rhokinase and transforming growth factor β pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201.
20. van Nieuw Amerongen GP, van Hinsbergh VW: Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol 2001; 21: 300-311.
21. Ishizawa K, Izawa Y, Ito H, et al: Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogenactivated protein kinase 1 activation. Hypertension 2005; 46: 1046-1052.
22. 2-terminal kinase activation. Mol Pharmacol 2004; 65: 832-841.
23. Salhia B, Rutten F, Nakada M, et al: Inhibition of Rhokinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res 2005; 65: 8792-8800.
24. Rupérez M, Rodrigues-Díez R, Blanco-Colio LM, et al: HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 2007; 50: 377-383.
25. Adami R, Cintio O, Trombetta G, Choquet D, Grazi E: On the stiffness of the natural actin filament decorated with alexa fluor tropomyosin. Biophys Chem 2003; 104: 469-476.
26. Sato A, Saruta T, Funder JW: Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006; 29: 211-216.
27. Ishizaki T, Uehata M, Tamechika I, et al: Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000; 57: 976-983.
28. Safar ME, Henry O, Meaume S: Aortic pulse wave velocity: an independent marker of cardiovascular risk. Am J Geriatr Cardiol 2002; 11: 295-298.
29. Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK: Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem 2001; 276: 341-347.
30. Kang DH, Park SK, Lee IK, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562.
31. Nishiguchi F, Fukui R, Hoshiga M, et al: Different migratory and proliferative properties of smooth muscle cells of coronary and femoral artery. Atherosclerosis 2003; 171: 39-47.
32. Kishi H, Bao J, Kohama K: Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J Biochem (Tokyo) 2000; 128: 719-722.
33. Kiian I, Tkachuk N, Haller H, Dumler I: Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb Haemost 2003; 89: 904-914.
34. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH: Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999; 84: 1186-1193.
35. Fu M, Zhang J, Tseng YH, et al: Rad GTPase attenuates vascular lesion formation by inhibition of vascular smooth muscle cell migration. Circulation 2005; 111: 1071-1077.
36. Liu Y, Suzuki YJ, Day RM, Fanburg BL: Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 2004; 95: 579-586.
37. Menard J, Gonzalez MF, Guyene TT, Bissery A: Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006; 24: 1157-1163.
38. Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303-310.
39. Takeda Y: Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens Res 2004; 27: 781-789.